Episode Summary

SURMOUNT-5 delivers the first head-to-head comparison of tirzepatide vs semaglutide in adults with obesity but without diabetes.
In this episode, host Dr. Diana Langworthy and expert guest Dr. Kylee Funk (clinical pharmacist in primary care at Mill City Clinic specializing in weight management and diabetes) unpack the trial's design, results, interpretation, safety considerations, and what these findings mean for real-world clinical practice.

• Tirzepatide achieved greater weight loss than semaglutide over 72 weeks.

• Both drugs improved cardiometabolic markers with similar safety profiles.

• Open-label design and exclusion criteria affect how broadly results apply.

• Clinical decisions still hinge on access, coverage, tolerability, and goals.

Want the full trial breakdown?
I created a deeper analysis, including statistics, estimands, subgroup data, and my extended critique on my What's it Worth? Substack.
Subscribe there for extra trial notes, bonus insights, and updates between episodes.

Aronne LJ, Bade Horn D, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394.

Diana Langworthy, PharmD, BCPS – Associate Professor, University of Minnesota College of Pharmacy

Kylee Funk, PharmD, BCPS – Clinical Pharmacist in Primary Care, Mill City Clinic (focus: weight management & diabetes)

Have a study you'd like us to decode on a future episode? Email whatsitworthpodcast@gmail.com.
Share comments or takeaways — I love hearing how you're using evidence in practice.
And for full-length study breakdowns and bonus content, subscribe at whatsitworthpodcast.substack.com.